Navin Fluorine Capex Plan: ₹600 Crore+ Expansion Across HFC, CDMO and Advanced Materials
Navin Fluorine International Limited (NAVINFLUOR) is pursuing an aggressive expansion strategy across high-performance products, specialty chemicals, CDMO, and emerging advanced materials.
The company’s latest investor presentation highlights multiple ongoing and new capital expenditure projects aimed at expanding manufacturing capacity, supporting new product launches, strengthening CDMO capabilities and developing new growth businesses.
The company is also investing in emerging applications such as data centres, electronics, defence and semiconductors, which management sees as important future growth markets.
Navin Fluorine Capex Plan: Multiple Projects Underway
Navin Fluorine has a number of capex projects at different stages of execution.
The major disclosed projects include:
- ₹236.5 crore for additional HFC capacity equivalent to up to 15,000 MTPA of R32
- ₹75 crore for debottlenecking MPP capacity at Dahej
- ₹125 crore for Phase II of the cGMP4 CDMO project
- ₹90 crore for Advanced Materials adoption capacities
- ₹120 crore for initial commercial capacity for an innovative liquid-cooling product
- ₹15.73 crore investment in a 14.9 MW hybrid renewable-power project
Taken together, these identified projects represent an investment of approximately ₹662 crore.
However, these projects have different purposes and timelines, so the amount should not be interpreted as a single new capex announcement or a one-time spending commitment.
₹236.5 Crore HFC Capacity Expansion
One of the major ongoing investments is the expansion of HFC capacity.
Navin Fluorine is investing ₹236.5 crore, funded through internal accruals, to add HFC capacity equivalent to up to 15,000 MTPA of R32.
The project is expected to be commissioned in Q3 FY27.
The company expects the project to benefit from a constructive global demand-supply environment driven by the transition towards lower-global-warming-potential gases, along with increasing RAC and blends demand in India and export markets.
The company estimates peak revenue potential of approximately ₹600–825 crore per year from this project.
The HFC business already showed strong growth in Q1 FY27, with revenue increasing to ₹540 crore from ₹407 crore, representing 33% year-on-year growth.
Management also said pricing conditions for HFC remain constructive and that there is increasing interest in contractual offtakes for new capacities.
AHF Facility Continues to Ramp Up
Navin Fluorine’s AHF facility commenced operations in Q4 FY26 and continues to ramp up.
The company views this as an important part of its High Performance Products business.
The HPP segment reported Q1 FY27 revenue of ₹540 crore, compared with ₹407 crore in Q1 FY26.
The company expects capacity additions and improved utilisation to support future growth in this business.
₹75 Crore Dahej Debottlenecking Project
Navin Fluorine is also undertaking a ₹75 crore debottlenecking project at Dahej for its MPP capacity.
The project is being funded through internal accruals and is targeted for commissioning in Q3 FY27.
The investment is linked to a new molecule launch for a global innovator.
The company said it has received strong projections from the global innovator to participate in its growth and has also received a purchase order for CY26.
The project has an estimated peak revenue potential of approximately ₹140–160 crore annually.
₹125 Crore CDMO Expansion
The CDMO business is another major focus area for Navin Fluorine.
The company has already approved total cGMP4 capex of ₹288 crore.
Phase I was operationalised in Q3 FY26, while Phase II, involving ₹125 crore of capex, has now been initiated and is expected to be operational by Q4 FY27.
The expansion is being supported by increasing demand for an existing molecule from a European CDMO major.
Navin Fluorine is also expanding its footprint in the customer’s supply chain.
The company expects the cGMP4 expansion to strengthen its position in the global pharmaceutical and biotech supply chain.
The presentation indicates an asset turnover of approximately 3x for the cGMP4 investment.
CDMO Business Showing Strong Growth
Navin Fluorine’s CDMO business delivered strong growth in Q1 FY27.
Revenue increased to ₹180 crore from ₹99 crore, representing 82% year-on-year growth.
Management attributed the momentum to the strong order book and deeper engagement with a European CDMO major.
The company is working across a portfolio of late/commercial-stage as well as early-stage molecules.
Its therapeutic-area pipeline includes:
- Oncology
- Respiratory
- Cardiovascular
- Neurology
- Animal health
This strategy is intended to create a balanced CDMO portfolio rather than relying on a single molecule or therapeutic segment.
₹90 Crore Investment in Advanced Materials
One of the most interesting parts of Navin Fluorine’s future strategy is the creation of an Advanced Materials business.
The company describes this as a new high-growth and high-margin business vertical for the future.
The strategy is based on leveraging Navin Fluorine’s existing fluorination capabilities for niche applications in emerging sectors such as:
- Data centres
- Electronics
- Defence
- Semiconductors
The company plans to invest ₹90 crore in adoption capacities to commercialise its product pipeline.
The project is targeted for completion by Q2 FY28.
The objective is to create commercial-scale qualification and adoption capacity and position the company to participate in future growth opportunities.
₹120 Crore Liquid-Cooling Product Investment
Navin Fluorine is also making an important investment in the emerging liquid-cooling market.
The company plans an initial commercial capacity for manufacturing an innovative liquid-cooling product.
The project involves ₹120 crore of capex, with approximately 35% funded by the customer and the balance through internal accruals.
The facility is targeted for commissioning by Q2 FY27.
The company believes this investment can help it establish an early position in advanced cooling solutions associated with data centres and other high-performance computing infrastructure.
This is strategically important because data-centre power density and heat-generation requirements are increasing as AI infrastructure expands.
Defence Opportunity Through DRDO Project
Navin Fluorine is also participating in an initiative aimed at indigenous development of a critical defence material.
The company highlighted a DRDO TDF project for indigenous process development.
The project is aligned with the company’s objective of developing new Advanced Materials applications and supporting AtmaNirbhar Bharat.
While the company has highlighted the strategic opportunity, investors should distinguish this initiative from a conventional large commercial order or established revenue stream.
Renewable Energy Investment
Navin Fluorine is also investing in renewable energy infrastructure.
The company plans an investment of ₹15.73 crore in an SPV for a 14.9 MW hybrid power project across NFIL and NFASL.
The investment is intended to increase renewable-energy adoption and support the company’s decarbonisation objectives.
The company expects the project to help meet more than 60% of its energy requirements from renewable sources.
This investment therefore has both sustainability and long-term operating-cost implications.
Future Strategy: Building Multiple Growth Platforms
Navin Fluorine’s future strategy is built around its 3P approach — Products, Platforms and Partnerships.
The company wants to strengthen its existing fluorochemical businesses while simultaneously building scalable platforms in CDMO and Advanced Materials.
The strategy includes:
- Expanding manufacturing capacity
- Developing new fluorination technologies
- Commercialising new products
- Increasing CDMO partnerships
- Entering advanced-material applications
- Strengthening R&D
- Expanding global customer relationships
- Investing in renewable energy
- Building long-term supply-chain partnerships
The objective is to create multiple growth engines rather than depending on one business segment.
Management’s Focus on R&D
Innovation is expected to remain an important component of Navin Fluorine’s future expansion strategy.
The company spent ₹48.71 crore on R&D in FY2025-26.
Its R&D activities focus on complex fluorinated products, pharmaceutical intermediates, KSMs and new specialty chemicals.
The company also has modern R&D centres in Surat, Dewas and Runcorn in Manchester.
Navin Fluorine is also planning digital transformation initiatives, including the implementation of Electronic Lab Notebooks (ELN) and Laboratory Information Management Systems (LIMS) to improve efficiency, traceability and compliance.
Strong Q1 FY27 Performance Provides Support for Expansion
The company’s expansion programme comes at a time when financial performance has improved significantly.
Consolidated Q1 FY27 revenue stood at ₹1,045.1 crore, up 44% year-on-year and 11% quarter-on-quarter.
Operating EBITDA increased 73% year-on-year to ₹357.1 crore, while EBITDA margin improved to 34.2% from 28.5% in Q1 FY26.
Operating PBT increased 101% to ₹283.3 crore.
Profit after tax increased 108% to ₹243.3 crore.
The strong operating performance provides the company with greater internal cash generation to support several of its expansion projects.
Management Commentary and Outlook
Navin Fluorine’s management is positioning the company for long-term growth through capacity expansion, innovation and strategic partnerships.
The company’s strategy is not limited to expanding existing businesses. Management is simultaneously trying to build new platforms in areas with potentially higher growth and margin characteristics.
The Advanced Materials initiative is particularly important because it targets sectors such as data centres, electronics, defence and semiconductors.
The CDMO strategy focuses on deeper engagement with global pharmaceutical innovators and increasing participation across the drug-development lifecycle.
In HPP, the company is expanding capacity to benefit from favourable demand conditions in lower-GWP refrigerants.
The overall strategy is therefore based on combining capacity expansion, product development, customer partnerships and technology-led differentiation.
Key Capex Projects to Track
Investors tracking Navin Fluorine should monitor the following milestones:
Q2 FY27
- Initial commercial capacity for liquid-cooling product
- Completion target for Chemours project
Q3 FY27
- Additional HFC capacity equivalent to up to 15,000 MTPA of R32
- Dahej MPP debottlenecking project
Q4 FY27
- Phase II cGMP4 capex of ₹125 crore
Q2 FY28
- Advanced Materials adoption capacity of ₹90 crore
These projects could progressively add manufacturing capacity and broaden the company’s revenue base.
Investor Takeaway
Navin Fluorine’s current expansion programme is notable because it combines capacity expansion in established businesses with investments in potentially high-growth emerging businesses.
The HFC expansion and Dahej debottlenecking are aimed at near-term capacity and revenue growth, while the cGMP4 investment strengthens the CDMO platform.
More strategically, the ₹90 crore Advanced Materials investment and ₹120 crore liquid-cooling project could help Navin Fluorine enter new growth markets linked to data centres, electronics, defence and semiconductors.
The company’s Q1 FY27 performance also provides a strong operating base, with revenue up 44% and EBITDA up 73% year-on-year.
However, investors should monitor project execution, commissioning timelines, customer adoption, capacity utilisation and returns on the new investments.
Overall, Navin Fluorine’s capex programme indicates a clear effort to move beyond traditional fluorochemicals and build multiple future growth engines across HPP, CDMO, specialty chemicals and Advanced Materials.